APPLICATION OF MONOCLONAL ANTIBODY FOR THE NEW TREATMENT AND DIAGNOSIS OF DIGESTIVE CANCER.

制备了人-小鼠嵌合抗体，并将抗癌药物neocarzinostatin与该嵌合抗体的Fab片段结合而不丧失其抗癌和抗体活性。临床1期研究已进行，并没有观察到严重的不良反应，高达40,000单位的免疫偶联物。与接受小鼠免疫偶联物的患者相比，接受嵌合抗体的患者的人抗小鼠抗体（HAMA）的产生被强烈抑制。精细铁磁性物已成功与抗体偶联。结合物的稳定性和与靶癌细胞结合的能力得到了很好的保存。实验动物肿瘤组织成像表明其在活体MRI成像中的应用价值。这种新型铁磁免疫偶联物在铁磁免疫引导下的手术应用前景广阔。

Huma/mouse chmeric antibody had been developed and anti-cancer drug neocarzinostatin could be bound with Fab fragment of chiemric antibody without loosing both anticancer and antibody activites. Clinical phase 1 study had been carried out and no seriouse adverse effects had been observed up to 40,000 units of immunoconojugates. The production of human anti-mouse antibody (HAMA) had been strongly suppressed in patients receiving chimeric antibody compared with patients receiving mouse immunocojugates.Fine ferromagnetics had been successfully conojugated with antibody. The stability and capacity of the cojugates to bind with target cancer cell had been well preserved. The imaging of tumor tissue in experimental animal suggested its usefullness in MRI imaging in vivo. This new ferromagnetic immunoconjugate could be applied for ferro-immuno-guided surgery in the near future.